Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
India has found thousands of dead ducks infected by a highly contagious bird flu virus in the southern state of Kerala
The outbreak of myiasis, also known as screw worm, stems from deteriorating water and sanitation conditions.
Joji Morishita, Japan's commissioner to the International Whaling Commission, said the new proposal is Tokyo's latest attempt to pursue sustainable whaling according to scientific principles.
In Europe, obesity is to blame for around 6.5 percent of all new cancers a year, or around 65,000 cases
Medical workers risking their lives to fight Ebola in West Africa talk about the challenges they face.
The woman 32, died at a fever hospital in the Nile Delta five days after she was admitted on contracting the virus, Hossam Abdel-Ghafar said
According to the World Health Organization, more than 80,000 children in Pakistan have not been immunized against polio
A total of 5,459 people have died in the worst Ebola outbreak on record, according the World Health Organization
Plague, a bacterial disease, is mainly spread from one rodent to another by fleas.
Felix Baez Sarria, the first Cuban to contract the deadly disease, will be treated in a Geneva hospital.
No Ebola cases detected for two incubation periods, says World Health Organization
The World Health Organization and leading global health specialists have criticised Saudi Arabia for failing to properly investigate the causes of MERS.
UNICEF predicts that the number of children orphaned by Ebola – which currently stands at nearly 200 – will reach as many as 2,000
UN Article 82 could mean millions in additional costs for drilling companies.
The figures, through Nov. 16, represent a jump of 243 deaths and 732 cases since those issued last Friday, and cases continue to be under-reported, the WHO said in its latest update.
The infectious disease causes total paralysis in a matter of hours. It affects mainly children under five years of age.